Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Priglinger, SG; Wolf, AH; Kreutzer, TC; Kook, D; Hofer, A; Strauss, RW; Alge, CS; Kunze, C; Haritoglou, C; Kampik, A.
Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Retina. 2007; 27(8):1004-1012
Doi: 10.1097/IAE.0b013e3180ed458d
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Strauß Rupert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injections on visual acuity and foveal retinal thickness in patients with central retinal vein occlusion (CRVO). Methods: In this prospective, noncomparative, consecutive, interventional case series, 46 patients received repeated intravitreal injections (1.25 mg) of bevacizumab. Main outcome measures were visual acuity (Snellen and ETDRS charts) and optical coherence tomography measurements in a 6-month follow-up period. Results: Mean visual acuity improved from 20/250 at baseline to 20/80 at the 6-month follow-up (P < 0.001). ETDRS chart findings revealed a mean letter gain +/- SD from baseline to 6 months of 13.9 +/- 14.4 letters. Mean central retinal thickness +/- SID decreased from 535 +/- 148 Am at baseline to 323 +/- 116 Am at the 6-month follow-up. Ischemic CRVO was associated with significantly lower visual acuity than nonischemic CRVO (P < 0.001). However, visual acuity gain was similar in both groups. Independent of duration of symptoms, CRVO was associated with a similar gain in visual acuity. Conclusion: Intravitreal injection of bevacizumab appears to be a new treatment option for patients with macular edema secondary to CRVO.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Angiogenesis Inhibitors - administration and dosage Angiogenesis Inhibitors - therapeutic use
- Antibodies, Monoclonal - administration and dosage Antibodies, Monoclonal - therapeutic use
- Antibodies, Monoclonal, Humanized -
- Female -
- Fluorescein Angiography -
- Follow-Up Studies -
- Humans -
- Injections -
- Macular Edema - drug therapy Macular Edema - etiology Macular Edema - physiopathology
- Male -
- Middle Aged -
- Prospective Studies -
- Retinal Vein Occlusion - complications Retinal Vein Occlusion - drug therapy Retinal Vein Occlusion - physiopathology
- Retreatment -
- Tomography, Optical Coherence -
- Treatment Outcome -
- Vascular Endothelial Growth Factor A - antagonists and inhibitors
- Visual Acuity - drug effects Visual Acuity - physiology
- Vitreous Body -
- Find related publications in this database (Keywords)
- bevacizumab
- central retinal vein occlusion
- intravitreal injection
- vascular endothelial growth factor